Last reviewed · How we verify
Glaucoma — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Phospholine Iodide | ECHOTHIOPHATE | Fera Pharms Llc | Cholinesterase Inhibitor | Acetylcholinesterase | 1960-01-01 | |
| Glanatec | Glanatec | Michael D. Straiko, MD | Serine/threonine-protein kinase TAO3, 5'-AMP-activated protein kinase subunit gamma-1, Aurora kinase B |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Glaucoma
- Fera Pharms Llc · 1 drug in Glaucoma
- Michael D. Straiko, MD · 1 drug in Glaucoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Glaucoma:
- Glaucoma treatment updates — RSS
- Glaucoma treatment updates — Atom
- Glaucoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Glaucoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/glaucoma. Accessed 2026-06-10.
Related
- Glaucoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing